North America Infectious Disease Therapeutics Market Research Report – Segmented By Mode Of Treatment, Target Organism, Infection Type, Distribution Channels and Country (the United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 1246
Pages: 182

North America Infectious Disease Therapeutics Market Size (2023 to 2028)

The size of the North American infectious disease therapeutics market is estimated to grow to USD 67.75 billion by 2028 from USD 46.45 billion in 2023, growing at a CAGR of 7.84% during the forecast period.

The prevalence of infectious diseases is high in North America, which is one of the potential factors leading to market growth. Bacteria, fungi, and viruses cause infectious diseases. Due to the increasing incidence of infectious diseases, the mortality rate also increases gradually. Some infectious diseases affecting many people are tuberculosis, Lyme, measles, sexually transmitted diseases, and others. Infectious diseases are caused mainly due to sedentary lifestyles and unhealthy habits, and a considerable amount of the population in North America has sedentary lifestyles, which is anticipated to drive the infectious disease therapeutics market.

Increasing advancements in infectious disease therapeutics to prevent and cure infectious diseases further boost the market growth in this region. The presence of key market participants in the North American region and their focus on developing effective therapeutic procedures to tackle infectious diseases is further anticipated to fuel the market's growth rate. In addition, rising awareness regarding treating infectious diseases pushes the market forward. The increased efforts of the governments to educate the people regarding infectious diseases support the market growth in this region. The U.S. government is conducting several programs to increase awareness around infectious diseases and the available treatment procedure. These awareness programs further include the significance of early detection of any infectious disease helps to give the proper treatment without having severe results.

However, high treatment costs associated with infectious diseases restrain the market growth. Furthermore, a shortage of skilled professionals also hampers market growth. In addition, the lack of safe and efficient drugs to treat infectious diseases impedes market growth.

This research report on the North America Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:

By Mode of Treatment:

  • Drugs     
  • Vaccines    

By Target Organism:

  • Antibacterial      
  • Antifungal
  • Antiviral  
  • Antiparasite      
  • others     

By Infection type: 

  • Bacterial  
  • Viral      
  • Fungal    
  • Parasitic  
  • Others    

By Distribution Channels: 

  • Hospitals  
  • Clinics     
  • Others

By Country:

  • The United States
  • Canada
  • Rest of North America

North America had the largest share of the global infectious disease therapeutics market in 2021, owing to the growing incidence of infectious diseases such as COVID-19 and increasing healthcare expenditure among the population. Rising government initiatives in this region to prevent infectious diseases such as HIV, influenza, and hepatitis is also helping the market in this region to grow further. Nearly 1.2 million people have HIV in the U.S., and many affected people do not know about the available treatment procedures. The U.S. government has done many awareness programs regarding HIV to reduce the spread of HIV disease to other people. In addition, the American government launched reimbursement policies for some chronic infectious diseases to take treatment in hospitals with minimal cost.

The U.S. market for infectious disease therapeutics is anticipated to account for a significant share of the North American region in 2021. YOY growth in the aging population favors the market growth in U.S. Infections are a significant cause of mortality in many older people. Nearly 1/3 of death are due to infectious diseases in older people. Early detection of this infection is difficult in older people due to the absence of signs. Due to the lack of this symptom, early diagnosis is needed for older people, which drives the market forward.

The Canadian market is expected to showcase a healthy CAGR during the forecast period. Different centers have been established by the Canadian Infectious Diseases Society's Clinical Studies Subcommittee to increase clinical trials on infectious diseases. In addition, the Canadian government has made a Canadian database for infectious diseases for practical medicine. This database helps in which infectious diseases are more in American people and helps to find the drugs and therapeutic for the priorities diseases to save people's lives. This database information also helps to take preventive measures for some diseases that can be preventable by noticing early detection in people.


A few of the key companies operating in the North America Infectious Disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida and Sanofi.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample